ҩѧÂÛÎÄ

Äúµ±Ç°µÄλÖãºÑ§ÊõÌà > ҽѧÂÛÎÄ > »ù´¡Ò½Ñ§ÂÛÎÄ > ҩѧÂÛÎÄ >

¸Ê²ÝËá¶Ô¶àÖÖ¸ÎÍâ¼²²¡µÄÖÎÁÆЧӦÑо¿×ÛÊö(2)

À´Ô´£ºÑ§ÊõÌà ×÷ÕߣºÖÜÀÏʦ
·¢²¼ÓÚ£º2015-09-12 ¹²4443×Ö

¡¡¡¡4 ¸Ê²ÝËá¶ÔÃâÒß¹¦ÄÜÎÉÂÒÏà¹Ø¼²²¡µÄÖÎÁÆ×÷ÓÃ

¡¡¡¡ÃâÒßÏà¹Ø¼²²¡ÍùÍù°éËæ×ŶàÖÖÑ×ÐÔÒò×ÓµÄÒì³£±í´ï£¬×÷ΪһÖÖ¿¹Ñ×Ò©Î¸Ê²ÝËáÒ²¿ÉÄÜÓÃÓÚÖÎÁÆÃâÒßÏà¹Ø¼²²¡¡£¶ÔСÊóÏø´­Ä£ÐͽøÐнâÆʺͷÎ×éÖ¯²¡Àí¼ì²é·¢ÏÖ£¬Ó밲ο¼Á×éÏà½Ï£¬¸Ê²ÝËáÊÔÑé×éµÄСÊó·Î×éÖ¯±­×´Ï¸°ûÊýÄ¿¡¢·Ê´óϸ°ûÊýÄ¿¡¢»ùµ×Ĥºñ¶È¡¢ÉÏƤϸ°ûÏÂƽ»¬¼¡²ãÊýµÈ¾ù¼õÉÙ£¬±íÃ÷¸Ê²ÝËá¿ÉÒÔÒÖÖÆÏø´­·¢²¡¹ý³ÌÖеıä̬·´Ó¦ºÍ×éÖ¯Öع¹£» ¸Ê²ÝËáÊÔÑé×éµÄÒÔÉÏÖ¸±êÓëµØÈûÃ×ËÉÖÎÁÆ×é±È½Ï²îÒìÎÞͳ¼ÆѧÒâÒ壬¿¼Âǵ½¼¤ËØÀàÒ©ÎïµÄ²»Á¼·´Ó¦£¬¸Ê²ÝËá¿ÉÄÜ×÷ΪÖÎÁÆÏø´­µÄÌæ´úÒ©Îµ«ÐèÒª¸üϵͳÉîÈëµÄÁÙ´²¶ÔÕÕÑо¿Ö¤ÊµÕâÒ»¼ÙÉè[25-26].

¡¡¡¡Éö²¡×ÛºÏÕ÷ÊÇÒ»ÖÖ×ÔÉíÃâÒßÐÔ¼²²¡£¬ÔÚ»¼ÕßÌåÄÚÓÐÒì³£µÄÃâÒß·´Ó¦¡£Ñо¿·¢ÏÖ£¬¸Ê²ÝËá¿ÉÒÔ¼õ»ºÉö²¡×ÛºÏÕ÷´óÊóÄ£ÐÍÉöÔà×éÖ¯ÖÐÑ×ÐÔϸ°û½þÈó£¬ÒÖÖÆ×éÖ¯ÖÐÑ×Ö¢Ïà¹Ø·Ö×Ó Èç ²ã Õ³ Á¬ µ° °×£¨ Laminine,LN£© ¡¢ÏËάÁ¬½Óµ°°×£¨ Fibronectin,FN£© ¡¢½ºÔ­µ°°× £¨ Collagen,COL£© ¡¢×ª»¯Éú³¤Òò×Ó β1£¨ Transforming growth factor beta1,TGF-β1£© ºÍ½áµÞ×éÖ¯Éú³¤Òò×Ó£¨ Connective tissue growth factor,CTGF£© µÄ±í´ï£¬½µµÍ´óÊóѪÇ弡ôû¡¢ÄòËصªµÈÖ¸±ê[27].Òøм²¡»¼Õß³£Ê¹ÓÃ×ÏÍâÖÎÁÆ£¬µ«ÊÇ×ÏÍâÖÎÁÆ¿ÉÌá¸ß»ùµ×Ĥµ°°×µÄÃâÒßÔ´ÐÔ£¬µ¼ÖÂ×ÔÉí¿¹ÌåµÄÐγɣ¬½ø¶øµ¼Ö´óðåÐÔÌìðå´¯µÄ·¢Éú¡£³öÏÖÒÔÉÏÖ¢×´µÄ»¼Õß½ÏΪº±¼û£¬Òò¶øҲȱÉÙ±ê×¼µÄÖÎÁÆ·½°¸¡£Si µÈ[28]֤ʵ£¬ÔÚʹÓüװ±µûßʽáºÏ¸Ê²ÝËáÖÎÁƺó£¬1 ÀýÓÐÉÏÊöÖ¢×´µÄ»¼Õߣ¬²¡ÇéµÃµ½ÁËÏÔ×Å»º½â¡£³ýÒÔ ÉÏ ¼² ²¡£¬¸Ê ²Ý Ëá »¹ ¶Ô »¼ ÓÐ Ñ× Ö¢ ÐÔ ³¦²¡[29-30]¡¢¹ýÃôÐÔ±ÇÑ×[31]µÄ¶¯ÎïÄ£ÐÍÓÐÁ¼ºÃµÄÖÎÁÆ×÷Ó㬾­¹ýÖÎÁÆ£¬¸Ê²ÝËáÖÎÁÆ×éµÄ¶¯ÎﲡÔî»òѪÇåµÄÑ×ÐÔ½þÈó¼õÉÙ£¬²¡Ç黺½â¡£

¡¡¡¡5 ¸Ê²ÝËáÔÚÆäËû¼²²¡ÖеÄÓ¦ÓÃ

¡¡¡¡»¼Óдúл×ÛºÏÕ÷µÄ´óÊó¼¡Èâ×éÖ¯ÖУ¬¹ýÑõ»¯ÎïøÌåÔöÖ³»î»¯ÊÜÌå 㣨 Peroxisome proliferator ac-tivated receptor gamma,PPAR-㣩 ¼°ÆÏÌÑÌÇתÔ˵°°× 4£¨ Glucose transporter 4,Glut-4£© ±í´ïˮƽϽµ£¬¶ø¶Ô¶¯Î︹ǻעÉä¸Ê²ÝËáºó£¬ÒÔÉÏ 2 ÖÖµ°°×µÄ±í´ïÉϵ÷£¬¶¯ÎïµÄÒȵºËصֿ¹ºÍ¸ßѪÌǵõ½»º½â[32].

¡¡¡¡½á¹û±íÃ÷£¬¸Ê²ÝËá¿ÉÒÔµ÷½ÚÖ¬·¾ËáÑõ»¯¼°ÌÇ´úлÎÈ̬£¬¿É×÷ΪÖÎÁÆ´úл×ÛºÏÕ÷µÄDZÔÚÒ©Îï¡£SenµÈ[33]µÃµ½ÏàËƽáÂÛ£¬¸Ê²ÝËá¿É»º½âÁ´ëåùËØÓÕµ¼µÄÌÇÄò²¡Ð¡ÊóµÄ²¡Çé¡£

¡¡¡¡¸Ê²ÝËáÔÚÖ×ÁöÖÎÁÆÖеÄ×÷Óá£Huang µÈ[34]Ñо¿Ö¤Êµ£¬¸Ê²ÝËá¿ÉÒÔͨ¹ýÒÖÖÆѪ˨ËغϳÉø£¨ Throm-boxane synthase,TxAS£© µÄ±í´ïºÍ»îÐÔ£¬ÒÖÖÆ·ÎÏÙ°©Ï¸°ûϵ A549 ϸ°ûÔöÖ³¡£ÁíÓÐÑо¿Ö¤Êµ£¬¸Ê²ÝËá¿ÉÒÔÔÚÌåÍâÓÕµ¼Ç°ÁÐÏÙ°©Ï¸°ûϵ DU-145¡¢LNCaP,¸Î°©Ï¸°ûϵ HLC,ÔçÓ×Á£Ï¸°ûϵ°×Ѫ²¡ HL60 ºÍθ°©Ï¸°ûϵ KATO¢óµÄµòÍö[35-36].¶¯ÎïÊÔÑé֤ʵ£¬¸Ê²ÝËá¿ÉÒÔ½µµÍ´Æ¼¤ËØÏà¹Ø×Ó¹¬ÄÚĤ°©ÔÚСÊóÖеķ¢²¡ÂÊ[37].

¡¡¡¡6 ½áÓï

¡¡¡¡ÒÔÍù¹úÄÚÍâ¶ÔÓڸʲÝËáÔÚÖÎÁƸÎÑס¢¸ÎÓ²»¯¡¢Ò©ÎïÐÔµÈÖ¸ÎË𺦵ÄÑо¿½Ï¶à£¬µ«½üÄêÑо¿·¢ÏָʲÝËáµÄÓ¦ÓüÛÖµ¿ÉÄܸü¹ã¡£±¾ÎÄϵͳ×ܽáÁ˸ʲÝËáÔÚ¸ÎÍâ¼²²¡ÖеÄÑо¿½øÕ¹¡£Î´À´¶Ô¸Ê²ÝËáµÄÑо¿£¬¿ÉÒÔ´ÓÒÔÏ 3 ¸ö·½Ïò¿ªÕ¹¡£

¡¡¡¡Ê×ÏÈ£¬ÈçÇ°ÎÄËùÊö£¬¸Ê²ÝËáÔÚ¸ÎÍâ¼²²¡µÄÑо¿´ó¶àÊÇ»ùÓÚ¶¯ÎïÄ£ÐÍ»òÕßϸ°ûʵÑ飬ÉÐȱÉÙÑϽ÷µÄÁÙ´²Ñо¿¡£ÓÉÓڸʲÝËáµÄ°²È«ÐÔÒѾ­µÃµ½Ö¤Êµ£¬ÈôÒªÑо¿¸Ê²ÝËáÔÚÖÎÁÆijһÖÖ¼²²¡ÖеĹ¦Ð§£¬¿ÉÒÔ¿ªÕ¹¸üÑϽ÷µÄ¶àÖÐÐÄ¡¢´óÑù±¾µÄËæ»ú¶ÔÕÕÁÙ´²Ñо¿£¬Îª¸Ê²ÝËáµÄÁÙ´²Ó¦ÓÃÌṩֱ½ÓµÄѭ֤ҽѧ֤¾Ý¡£

¡¡¡¡Æä´Î£¬¸Ê²ÝËáµÄ¹¦Äܲ»½öÏÞÓÚÖ±½ÓÖÎÁƼ²²¡£¬»¹¿ÉÄÜÓÃÓÚ»º½âÆäËûÒ©ÎïʹÓùý³ÌÖвúÉúµÄ²»Á¼·´Ó¦¡£ÈçƤÖÊ´¼ÀàÒ©Îï¿ÉÒÔÓÕµ¼ÑÛÄÚѹÔö¸ß£¬¶ÔÓÚÃô¸ÐÕß»áÔì³ÉÇà¹âÑÛ»òÕß¼ÓÖØÇà¹âÑÛµÄÖ¢×´¡£

¡¡¡¡Óб¨µÀ£¬¸Ê²ÝËá¿ÉÒÔÏÔ×ÅÒÖÖÆƤÖÊ´¼ÀàÒ©Îï - Çú°²ÄεÂÓÕµ¼µÄÐÂÎ÷À¼°×ÍÃÑÛÄÚѹÔö¸ß[38].Ìáʾ¶ÔÓÚÃô¸Ð»¼Õߣ¬¸Ê²ÝËá¿ÉÒÔ×÷ΪƤÖÊ´¼Ò©ÎïµÄ²¹³äÒ©ÎԤ·À»òÖÎÁƺóÕßÔì³ÉµÄÑÛÄÚѹÔö¸ß¡£´ËÍ⣬¸Ê²ÝËá¿ÉÒÔÌá¸ß¶àÖÖÒ©ÎïµÄÖÎÁÆ×÷Óã¬Æä»úÖÆÊÇ¿ÉÒÔÔö¼Óϸ°ûĤµÄͨ͸ÐÔ£¬´Ù½øϸ°û¶ÔÒ©ÎïµÄÉúÎïÀûÓÃÂÊ[39].Ä¿Ç°£¬¹ØÓڸʲÝËáÔÚÕâÁ½¸öÁìÓòµÄÑо¿½ÏÉÙ£¬ËùÒÔÔÚÁÙ´²ÖУ¬¸Ê²ÝËáÓëÆäËûÒ©ÎïÅäÎé¶ÔÁÆЧµÄÓ°Ï죬ҲÊǷdz£ÓÐÒâÒåµÄÑо¿·½Ïò¡£

¡¡¡¡×îºó£¬ÐèҪעÒâµÄÊÇ£¬Ä¿Ç°Ó¦ÓÃÓÚ»¤¸Î½µÃ¸ÖÎÁƵÄÒì¸Ê²ÝËáþ¾ßÓи߶ȵĸÎÔàÇ׺ÍÐÔ¡£ËùÒÔ£¬ÈçºÎͨ¹ý¶Ô¸Ê²ÝËá½øÐиĹ¹ºÍÐÞÊΣ¬Ìá¸ßÒ©ÎïÔÚÆäËûÆ÷¹ÙºÍ×éÖ¯Öеĸ»¼¯³Ì¶È£¬¶ÔÓÚÍƹã¸Ê²ÝËáÀàÒ©ÎïµÄÓ¦ÓþßÓоö¶¨ÐÔÒâÒå¡£

¡¡¡¡²Î¿¼ÎÄÏ×£º

¡¡¡¡[1] Ye S,Zhu Y,Ming Y,et al. Glycyrrhizin protects mice againstrenal ischemia-reperfusion injury through inhibition of apopto-sis and inflammation by downregulating p38 mitogen-activatedprotein kinase signaling[J]. Exp Ther Med,2014,7£¨ 5£© : 1247-1252.

¡¡¡¡[2] Orlent H,Hansen BE,Willems M,et al. Biochemical and his-tological effects of 26 weeks of glycyrrhizin treatment in chro-nic hepatitis C: a randomized phase II trial[J]. J Hepatol,2006,45£¨ 4£© : 539-546.

¡¡¡¡[3] Mao YM,Zeng MD,Chen Y,et al. Magnesium isoglycyrrhiz-inate in the treatment of chronic liver diseases: a randomized,double-blind,multi-doses,active drug controlled,multi-centerstudy[J]. Zhonghua Gan Zang Bing Za Zhi,2009,17 £¨ 11 £© :847-851.

¡¡¡¡[4] Zhai CL,Zhang MQ,Zhang Y,et al. Glycyrrhizin protects ratheart against ischemia-reperfusion injury through blockade ofHMGB1-dependent phospho-JNK / Bax pathway [J]. ActaPharmacol Sin,2012,33£¨ 12£© : 1477-1487.

Ïà¹ØÄÚÈÝÍƼö
Ïà¹Ø±êÇ©£º
·µ»Ø£ºÒ©Ñ§ÂÛÎÄ